ProteinLogic appoints Dr. Berwyn Clarke as new Non-Executive Director

CAMBRIDGE, UK (2012-07-31) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Berwyn Clarke as a Non-Executive Director.  Dr Clarke joins the ProteinLogic Board with 25 years’ experience in diagnostics and pharmaceuticals working for start-ups and global businesses such as GlaxoWellcome and Bayer Diagnostics. He is Founder and Chief Scientific Officer of Lab21 Ltd, a rapidly growing healthcare diagnostics business, providing state-of-the-art diagnostic infectious disease products to blood-banks and clinical labs on a worldwide basis; molecular diagnostic products; and molecular diagnostic services in personalised medicine, mainly in oncology. Dr Clarke played a leading role in taking Lab21 from a start-up in 2005 to a significant global player in diagnostic products and services today with service operations in Europe and North America and sales into over 130 countries.

ProteinLogic’s Chairman Dr Paul Rodgers said: “I am delighted that Berwyn has joined the Board where his business and diagnostics industry expertise will help commercialisation of the Company’s ImmiPrint® biomarker technology. The Board believes that Berwyn’s skills, knowledge and expertise will help progress the Company’s development plans to the next stage.”

Dr Clarke said: “I am thrilled to be joining the Company at this exciting stage of its development and I am looking forward to working with the ProteinLogic team.

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has

developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.

ProteinLogic’s development pipeline comprises 14 different ImmiPrint® signatures in disease areas including infectious, inflammatory, autoimmune, oncology and metabolic diseases. Following commercial analysis, the Company has identified a significant unmet need for a simple, rapid, and inexpensive blood test that is capable of diagnosing tuberculosis (TB). Early clinical studies indicate that the ImmiPrint® TB signature may be able to discriminate between active and latent forms of TB.

www.proteinlogic.com